This Article Full Text Full Text (PDF) All Versions of this Article: bjo.2006.113902v1 91/10/1318    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lux, A. Articles by Joussen, A. M Search for Related Content PubMed PubMed Citation Articles by Lux, A. Articles by Joussen, A. M Topic Collections Relevant Article

Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions

Department of Ophthalmology, University of Düsseldorf, Düsseldorf, Germany and Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Cologne, Germany

Correspondence to:
Antonia M Joussen, Department of Ophthalmology, University of Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany; Joussena{at}googlemail.com

Aims: To determine the characteristics of "non-responders" to intravitreal bevacizumab treatment in choroidal neovascularisation (CNV).

Methods: Forty-three patients with visual loss due to neovascular age-related macular disease (ARMD) (44 eyes) underwent intravitreal injections of 1.25 mg (0.05 ml) bevacizumab and were followed up every 4 weeks for 2, 3 or 6 months. Re-injection was performed when persistent leakage of the CNV was determined by fluorescein angiography and retinal oedema was assessed by optical coherence tomography (OCT). Non-responders were defined as those patients having reduced or stable visual acuity at the last follow-up.

Results: 45% of the patients were non-responders. In this group the initial CNV size was significantly larger than in the responders. Initial reading ability was significantly lower in non-responders, but the initial foveal oedema was similar in both groups. Gains in mean visual acuity and reading ability were independent of lesion type. The proportion of non-responders to responders in the different lesion type groups was equally distributed. Only patients with the classic type of CNV seemed to respond better.

Conclusions: In this study initial reasons for non-responders to intravitreal bevacizumab treatment in CNV are given. The efficiency of bevacizumab depends on initial lesion size and initial reading ability, but is independent of the amount of intraretinal and subretinal fluid. There was no general ineffectiveness of bevacizumab with any particular lesion type.

Abbreviations: ARMD, age-related macular disease; CNV, choroidal neovascularisation; OCT, optical coherence tomography; PED, pigment epithelial detachment; PDT, photodynamic therapy; VEGF, vascular endothelial growth factor

Relevant Article

Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?

Silvia Bopp
Br. J. Ophthalmol. 2007 91: 1259-1260. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				N Nigam, J Hedaya, and W R Freeman Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions Br. J. Ophthalmol., June 1, 2008; 92(6): 864 - 865. [Full Text] [PDF]

				S. Bopp Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy? Br. J. Ophthalmol., October 1, 2007; 91(10): 1259 - 1260. [Full Text] [PDF]